Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S.A.
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a formal convocation (“Convocatoria”) of the ORYZON Genomics 2026 Annual General Meeting, including the full agenda, proposals, instructions on documentation availability, shareholder rights to cast votes or grant proxies, and remote attendance guidelines. It is not the AGM materials themselves nor the results; rather, it solicits shareholder votes and provides information in advance of the meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-22 Spanish
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S.A.
Proxy Solicitation & Information Statement Classification · 85% confidence The document is the formal convocation (notice) of the Annual General Meeting of Shareholders, including the full agenda, proposals for resolution, shareholder rights, and instructions for attendance, representation, and voting. This aligns with materials sent to shareholders to provide information and request votes for the meeting. Therefore, it is best classified as a Proxy Solicitation & Information Statement.
2026-05-22 Spanish
La Sociedad remite información sobre los Resultados del primer trimestre de 2026
Earnings Release Classification · 90% confidence The document is a press release (“Nota de prensa”) announcing the company’s first–quarter 2026 financial results and operational highlights. It contains high-level quarter–end figures (net loss, R&D spend, cash position) and clinical development updates, but is not the full interim report itself. This matches an Earnings Release. Q1 2026
2026-05-14 Spanish
La sociedad remite información financiera del segundo semestre de 2025
Regulatory Filings
2026-02-27 Spanish
La sociedad remite el Informe Financiero Anual del ejercicio 2025
Regulatory Filings
2026-02-27 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2025
Remuneration Information Classification · 100% confidence The document is a detailed report titled 'Política de Remuneraciones' (Remuneration Policy) for the company Oryzon Genomics, S.A. It outlines the compensation structure for directors, including fixed and variable components, risk mitigation measures, and governance of remuneration. This content is specifically designed to be presented to shareholders for approval or disclosure, which aligns with the 'DEF 14A' category (Remuneration Information/Proxy Statement materials).
2026-02-27 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.